{"product_id":"p-21","title":"P-21","description":"\u003cp dir=\"auto\"\u003e\u003cstrong\u003eP-21\u003c\/strong\u003e (also known as \u003cstrong\u003eP021\u003c\/strong\u003e, \u003cstrong\u003ePeptide 021\u003c\/strong\u003e, or \u003cstrong\u003eGLXC-21260\u003c\/strong\u003e) is a \u003cstrong\u003esynthetic adamantane-modified tetrapeptide\u003c\/strong\u003e derived from a biologically active region (residues 148–151) of \u003cstrong\u003eciliary neurotrophic factor\u003c\/strong\u003e (\u003cstrong\u003eCNTF\u003c\/strong\u003e). This research compound was rationally designed to capture the neurotrophic and neurogenic properties of full-length CNTF while overcoming its limitations (poor blood-brain barrier penetration, short half-life, and side effects such as anorexia and weight loss). The addition of an adamantylated glycine at the C-terminus enhances lipophilicity, metabolic stability, and CNS accessibility, enabling oral administration in research models.\u003c\/p\u003e\n\u003cp dir=\"auto\"\u003ePreliminary and advanced preclinical studies demonstrate that P21 promotes hippocampal neurogenesis, upregulates \u003cstrong\u003eBDNF\u003c\/strong\u003e expression, competitively inhibits leukemia inhibitory factor (\u003cstrong\u003eLIF\u003c\/strong\u003e) signaling, reduces tau hyperphosphorylation (via GSK-3β modulation), and improves cognitive performance in models of aging and Alzheimer’s disease. Researchers utilize P21 in laboratory and animal models to investigate mechanisms of adult neurogenesis, synaptic plasticity, tauopathy, and neurotrophic support. As a research-grade compound, P21 is intended exclusively for in vitro and animal studies. Scientists value its oral bioavailability, small size, dual BDNF\/LIF mechanism, and consistent disease-modifying effects observed in 3xTg-AD and aged rodent models.\u003c\/p\u003e\n\u003ch3 dir=\"auto\"\u003eKey Research Applications\u003c\/h3\u003e\n\u003cul dir=\"auto\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eNeurogenesis and Synaptic Plasticity\u003c\/strong\u003e — Preclinical studies show increased proliferation and survival of neural progenitor cells in the dentate gyrus, elevated BDNF levels, enhanced synaptic markers (e.g., synaptophysin, PSD-95), and improved long-term potentiation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCognitive Enhancement and Aging\u003c\/strong\u003e — Chronic oral administration rescues spatial learning and memory deficits in aged rats and restores performance to near wild-type levels in Alzheimer’s transgenic models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAlzheimer’s Disease and Tau Pathology\u003c\/strong\u003e — In 3xTg-AD mice, P21 reduces hyperphosphorylated tau at multiple epitopes, decreases neurofibrillary pathology, and in some paradigms lowers amyloid burden, with benefits observed even when treatment is initiated after pathology onset.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNeuroprotection and Developmental Models\u003c\/strong\u003e — Early postnatal or prenatal-to-postnatal treatment prevents later Alzheimer-like behavioral and synaptic deficits. Additional work explores benefits in Down syndrome (Ts65Dn) models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMechanism-Focused Research\u003c\/strong\u003e — Dual action of LIF pathway inhibition (favoring neural stem cell proliferation) combined with BDNF upregulation provides a targeted tool for studying neurotrophic deficits in neurodegeneration and cognitive aging.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Omni Peptides","offers":[{"title":"10 MG","offer_id":51018138779895,"sku":"P210","price":1100.0,"currency_code":"AED","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0918\/6777\/5223\/files\/p-21-10mg.png?v=1788037148","url":"https:\/\/dubaipeptides.ae\/products\/p-21","provider":"Dubai Peptides","version":"1.0","type":"link"}